

# CSPC Pharmaceutical (1093 HK)

## Landmark BD deal to drive long-term growth

- **Landmark US\$18.5bn+ out-licensing deal with AstraZeneca.** CSPC has entered into a strategic collaboration with AstraZeneca (AZ) to advance eight weight management and type 2 diabetes programs. This partnership complements AZ's existing pipeline which includes oral GLP1RA, injectable amylin RA and GLP-1/GCGR assets, while significantly validating CSPC's proprietary AI-driven discovery and sustained-release monthly dosing peptide platforms. The agreement grants AstraZeneca exclusive global rights (excluding Greater China) to a portfolio of innovative long-acting peptide medicines, anchored by SYH2082 (a clinical-ready long-acting GLP1R/GIPR agonist) and comprising three obesity-related preclinical assets plus four future new programs. Under the terms, CSPC will lead development through PhI completion for the initial assets. The transaction features a substantial US\$1.2bn upfront payment, potential milestones totaling up to US\$17.3bn, and double-digit royalties.
- **Sustainable out-licensing income stream.** Beyond the recent landmark partnership with AZ, CSPC has established a strong track record of business development (BD). Since late 2024, the Company has signed six out-licensing agreements covering a diverse array of assets—including an Lp(a) inhibitor, MAT2A inhibitor, ROR1 ADC, oral GLP-1, irinotecan liposome, and an AI-driven small molecule discovery platform. These transactions continuously validate CSPC's drug discovery capabilities. Furthermore, CSPC has cultivated a deep pipeline containing several late-stage or differentiated candidates which we believe hold high out-licensing potential, such as B7-H3 ADC, PD-1/IL-15 bsAb, GFRAL mAb, and ActRII mAb. In our view, CSPC is on track to generate a sustainable and recurring stream of BD income over the medium to long term.
- **Sales mildly recovered in 3Q25.** CSPC reported total revenue of RMB19.9bn for 9M25, including RMB1.54bn in out-licensing (BD) income. Excluding BD contributions, core revenue reached RMB18.4bn, down 19% YoY. However, signs of recovery emerged in 3Q25, with core revenue (ex-BD) returning to growth, increasing 4.2% QoQ. Modest sequential improvement was observed across key therapeutic areas, including neurology, oncology, anti-infectives, and cardiovascular products. Looking ahead, we expect drug sales to stabilize in 2026E. On the cost side, the selling expense ratio shrank significantly from 29.2% in 9M24 to 24.1% in 9M25. Meanwhile, R&D investment remained the Company's priority, with R&D expenses rising 7.9% YoY to RMB4.2bn in 9M25 (21.0% R&D expense ratio). We also anticipate a sustainable dividend payout, supported by upfront payments from recent BD deals.
- **Maintain BUY.** CSPC's BD deals will be a key sustainable driver of earnings growth. Considering the landmark deal with AZ, we revise up our earnings forecasts in model and adjust our DCF-based TP from HK\$11.05 to HK\$13.93 (WACC 9.34%, terminal growth 3.0%).
- **Risks:** Pipeline advancement delays; negative impact from VBP on commercial products.

### Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (RMB mn)	31,450	29,009	26,949	28,628	30,656
YoY growth (%)	1.7	(7.8)	(7.1)	6.2	7.1
Net profit (RMB mn)	6,072.7	4,338.8	4,945.1	6,634.5	8,514.1
YoY growth (%)	(2.6)	(28.6)	14.0	34.2	28.3
EPS (Reported) (RMB)	0.49	0.37	0.43	0.57	0.73
P/E (x)	17.3	23.2	20.1	14.9	11.6
Net gearing (%)	(37.3)	(23.5)	(30.1)	(32.6)	(35.8)

Source: Company data, Bloomberg, CMBIGM estimates

## BUY (Maintain)

<b>Target Price</b>	<b>HK\$13.93</b>
(Previous TP)	HK\$11.05)
<b>Up/Downside</b>	<b>45.1%</b>
<b>Current Price</b>	<b>HK\$9.60</b>

### China Healthcare

#### Jill WU, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

#### Andy WANG

(852) 3657 6288

andywang@cmbi.com.hk

### Stock Data

Mkt Cap (HK\$ mn)	114,405.2
Avg 3 mths t/o (HK\$ mn)	1,042.9
52w High/Low (HK\$)	11.48/4.46
Total Issued Shares (mn)	11917.2

Source: FactSet

### Shareholding Structure

Cai Dongchen	11.3%
Massive Giant Group Ltd	10.6%


Source: Bloomberg

### Share Performance

	Absolute	Relative
1-mth	12.9%	6.6%
3-mth	28.5%	23.3%
6-mth	-5.0%	-12.6%

Source: FactSet

### 12-mth Price Performance



Source: FactSet

Figure 1: Out-licensing deals of CSPC

Date	Partner	Products	Upfront payment (US\$mn)	Milestone (development + sales) & royalties	Regions	Sources
2026.01.30	AstraZeneca	Weight management portfolio, (eight programs including SYH2082, based on the AI-driven peptide drug discovery platform and once-monthly dosing platform)	1,200	US\$17.3bn & royalties	Outside of Greater China	<a href="#">Link</a>
2025.07.30	Madrigal	SYH2086 (Oral GLP-1 at pre-clinical stage)	120	US\$1,955mn & royalties	Global	<a href="#">Link</a>
2025.6.13	AstraZeneca	AI-driven oral small molecule drug discovery platform	110	US\$1,620+3,600mn & royalties	Global	<a href="#">Link</a>
2025.5.15	Cipla USA	Irinotecan liposome injection	15	US\$25+1,025mn & royalties	US	<a href="#">Link</a>
2025.2.18	Radiance Biopharma	SYS6005 (ROR1 ADC)	15	US\$150+1,075mn & royalties	US, EU, UK, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada.	<a href="#">Link</a>
2024.12.12	BeOne	SYH2039 (MAT2A inhibitor)	150	US\$135+1,550mn & royalties	Global	<a href="#">Link</a>
2024.10.7	AstraZeneca	YS2302018 (lipoprotein (a) inhibitor)	100	US\$370+1,550mn & royalties	Global	<a href="#">Link</a>
2023.2.23	Corbus Pharma	SYS6002 (Nectin-4 ADC)	8	US\$130+555mn & royalties	US, EU, UK, Canada, etc	<a href="#">Link</a>
2022.7.28	Elevation Oology	SYSA1801 (Claudin18.2 ADC)	27	US\$148+1,020mn & royalties	Outside of Greater China	<a href="#">Link</a>
2021.8.17	Flame Biosciences	NBL-015 (Claudin 18.2 mAB)	8	US\$172.5+460mn & royalties	Outside of Greater China	<a href="#">Link</a>

Source: Company data, CMBIGM

Figure 2: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	8,171	10,430	11,160	11,885	12,598	13,291	13,956	14,584	15,167	15,698
Tax rate	17%	17%	17%	17%	17%	17%	17%	17%	17%	17%
EBIT*(1-tax rate)	6,746	8,611	9,214	9,813	10,402	10,974	11,522	12,041	12,523	12,961
+ D&A	1,336	1,336	1,430	1,523	1,614	1,703	1,788	1,868	1,943	2,011
- Change in working capital	(678)	(862)	(922)	(982)	(1,041)	(1,098)	(1,153)	(1,205)	(1,253)	(1,297)
- Capex	(2,015)	(2,015)	(2,015)	(2,015)	(2,015)	(2,015)	(2,015)	(2,015)	(2,015)	(2,015)
FCFF	5,389	7,070	7,706	8,338	8,960	9,563	10,142	10,689	11,197	11,660
Terminal value										189,350
Terminal growth rate	3.00%									
WACC	9.34%									
Cost of Equity	13.00%									
Cost of Debt	3.00%									
Equity Beta	1.00									
Risk Free Rate	2.50%									
Market Risk Premium	10.50%									
Target Debt to Asset ratio	35.00%									
Effective Corporate Tax Rate	15.00%									
Terminal value (RMB mn)	77,513									
Total PV (RMB mn)	131,856									
Net debt (RMB mn)	(12,473)									
Minority interests (RMB mn)	1,494									
Equity value (RMB mn)	142,835									
# of shares (mn)	11,522									
DCF per share (in HK\$)	13.93									

Source: CMBIGM estimates

Figure 3: Sensitivity analysis (HK\$)

		WACC				
		8.34%	8.84%	9.34%	9.84%	10.34%
Terminal growth rate	4.00%	18.86	16.97	15.43	14.16	13.09
	3.50%	17.55	15.94	14.62	13.50	12.55
	3.00%	16.48	15.09	13.93	12.94	12.08
	2.50%	15.59	14.38	13.34	12.45	11.67
	2.00%	14.85	13.77	12.84	12.03	11.31

Source: Company data, CMBIGM estimates

Figure 4: CMBIGM estimates: New vs Old

RMB mn	New			Old			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	26,949	28,628	30,656	26,949	27,997	29,323	0.0%	2.3%	4.5%
Gross profit	17,712	19,505	21,736	17,712	18,378	19,487	0.0%	6.1%	11.5%
Operating profit	6,078	8,171	10,430	6,078	6,723	7,233	0.0%	21.5%	44.2%
Attributable net profit	4,907	6,583	8,449	4,907	5,397	5,830	0.0%	22.0%	44.9%
EPS (RMB)	0.43	0.57	0.73	0.43	0.47	0.51	0.0%	22.0%	44.9%
Gross margin	65.72%	68.13%	70.91%	65.72%	65.64%	66.46%	0ppt	+2.49ppt	+4.45ppt
Operating margin	22.55%	28.54%	34.02%	22.55%	24.01%	24.67%	0ppt	+4.53ppt	+9.36ppt
Net margin	18.21%	23.00%	27.56%	18.21%	19.28%	19.88%	0ppt	+3.72ppt	+7.68ppt

Source: Company data, CMBIGM estimates

Figure 5: CMBIGM estimates vs consensus

RMB mn	CMBI			Consensus			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	26,949	28,628	30,656	27,874	29,500	30,916	-3.3%	-3.0%	-0.8%
Gross profit	17,712	19,505	21,736	18,754	20,048	20,977	-5.6%	-2.7%	3.6%
Operating profit	6,078	8,171	10,430	5,944	6,601	6,606	2.3%	23.8%	57.9%
Attributable net profit	4,907	6,583	8,449	4,937	5,081	5,305	-0.6%	29.6%	59.3%
EPS (RMB)	0.43	0.57	0.73	0.43	0.45	0.46	-1.4%	28.4%	60.8%
Gross margin	65.72%	68.13%	70.91%	67.28%	67.96%	67.85%	-1.56ppt	+0.17ppt	+3.06ppt
Operating margin	22.55%	28.54%	34.02%	21.32%	22.38%	21.37%	+1.23ppt	+6.17ppt	+12.65ppt
Net margin	18.21%	23.00%	27.56%	17.71%	17.22%	17.16%	+0.5ppt	+5.77ppt	+10.4ppt

Source: Bloomberg, CMBIGM estimates

## Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
<b>Revenue</b>	<b>30,937</b>	<b>31,450</b>	<b>29,009</b>	<b>26,949</b>	<b>28,628</b>	<b>30,656</b>
Cost of goods sold	(8,680)	(9,273)	(8,711)	(9,237)	(9,123)	(8,919)
<b>Gross profit</b>	<b>22,256</b>	<b>22,177</b>	<b>20,299</b>	<b>17,712</b>	<b>19,505</b>	<b>21,736</b>
Selling expense	(10,337)	(9,141)	(8,662)	(6,460)	(6,164)	(6,194)
Admin expense	(1,173)	(1,190)	(1,080)	(818)	(863)	(867)
R&D expense	(3,987)	(4,830)	(5,191)	(5,525)	(5,548)	(5,575)
Others	815	421	346	1,168	1,241	1,329
<b>Operating profit</b>	<b>7,574</b>	<b>7,437</b>	<b>5,712</b>	<b>6,078</b>	<b>8,171</b>	<b>10,430</b>
Gain/loss on financial assets at FVTPL	0	0	0	0	0	0
Share of (losses)/profits of associates/JV	33	(21)	(89)	(53)	(100)	(100)
<b>Net Interest income/(expense)</b>	<b>(25)</b>	<b>(26)</b>	<b>(44)</b>	<b>(36)</b>	<b>(35)</b>	<b>(18)</b>
<b>Pre-tax profit</b>	<b>7,582</b>	<b>7,389</b>	<b>5,579</b>	<b>5,990</b>	<b>8,036</b>	<b>10,312</b>
Income tax	(1,350)	(1,317)	(1,240)	(1,044)	(1,401)	(1,798)
Minority interest	141	199	11	38	51	66
<b>Net profit</b>	<b>6,232</b>	<b>6,073</b>	<b>4,339</b>	<b>4,945</b>	<b>6,635</b>	<b>8,514</b>
Gross dividends	2,097	2,726	2,597	2,454	3,292	4,224
Net dividends	9	(4)	(26)	13	34	28

BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
<b>Current assets</b>	<b>23,957</b>	<b>26,745</b>	<b>21,888</b>	<b>24,229</b>	<b>26,777</b>	<b>30,182</b>
Cash & equivalents	10,298	12,015	6,777	9,671	11,655	14,403
Account receivables	4,631	6,542	6,048	5,618	5,968	6,391
Inventories	2,555	3,139	3,130	3,319	3,278	3,205
Prepayment	0	0	0	0	0	0
ST bank deposits	3,575	1,077	1,307	1,307	1,307	1,307
Other current assets	2,898	3,972	4,626	4,314	4,568	4,876
<b>Non-current assets</b>	<b>17,813</b>	<b>19,537</b>	<b>22,501</b>	<b>23,180</b>	<b>23,859</b>	<b>24,538</b>
PP&E	9,582	10,417	11,374	12,366	13,358	14,350
Deferred income tax	113	187	250	250	250	250
Intangibles	1,908	2,199	2,610	2,460	2,311	2,162
Goodwill	1,395	1,226	1,128	965	801	637
Financial assets at FVTPL	2,126	2,387	2,334	2,334	2,334	2,334
Other non-current assets	2,689	3,122	4,804	4,804	4,804	4,804
<b>Total assets</b>	<b>41,770</b>	<b>46,282</b>	<b>44,389</b>	<b>47,409</b>	<b>50,636</b>	<b>54,720</b>
<b>Current liabilities</b>	<b>8,958</b>	<b>10,183</b>	<b>9,634</b>	<b>10,155</b>	<b>10,031</b>	<b>9,817</b>
Short-term borrowings	153	450	392	383	374	365
Account payables	6,864	8,404	7,409	7,857	7,760	7,587
Tax payable	262	379	138	138	138	138
Other current liabilities	1,679	948	1,695	1,777	1,759	1,728
<b>Non-current liabilities</b>	<b>1,170</b>	<b>1,082</b>	<b>889</b>	<b>889</b>	<b>889</b>	<b>889</b>
Long-term borrowings	0	0	0	0	0	0
Other non-current liabilities	1,170	1,082	889	889	889	889
<b>Total liabilities</b>	<b>10,128</b>	<b>11,264</b>	<b>10,523</b>	<b>11,043</b>	<b>10,920</b>	<b>10,706</b>
Share capital	10,899	10,899	11,033	11,139	11,246	11,352
Other reserves	19,298	22,304	21,232	23,685	26,977	31,201
<b>Total shareholders equity</b>	<b>30,198</b>	<b>33,203</b>	<b>32,265</b>	<b>34,825</b>	<b>38,223</b>	<b>42,554</b>
Minority interest	1,444	1,815	1,602	1,541	1,494	1,461
<b>Total equity and liabilities</b>	<b>41,770</b>	<b>46,282</b>	<b>44,389</b>	<b>47,409</b>	<b>50,636</b>	<b>54,720</b>

<b>CASH FLOW</b>	<b>2022A</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec (RMB mn)</b>						
<b>Operating</b>						
Profit before taxation	7,582	7,389	5,579	5,990	8,036	10,312
Depreciation & amortization	1,048	1,114	1,336	1,336	1,336	1,336
Tax paid	(1,335)	(1,309)	(1,693)	(1,044)	(1,401)	(1,798)
Change in working capital	798	(3,032)	(817)	1,082	(678)	(862)
Others	(467)	16	130	0	0	0
<b>Net cash from operations</b>	<b>7,627</b>	<b>4,179</b>	<b>4,535</b>	<b>7,363</b>	<b>7,293</b>	<b>8,989</b>
<b>Investing</b>						
Capital expenditure	(2,220)	(1,624)	(2,015)	(2,015)	(2,015)	(2,015)
Acquisition of subsidiaries/ investments	0	0	(80)	0	0	0
Others	(4,576)	2,231	(1,763)	0	0	0
<b>Net cash from investing</b>	<b>(6,796)</b>	<b>607</b>	<b>(3,858)</b>	<b>(2,015)</b>	<b>(2,015)</b>	<b>(2,015)</b>
<b>Financing</b>						
Dividend paid	(2,097)	(2,726)	(3,234)	(2,454)	(3,292)	(4,224)
Net borrowings	486	0	28	0	0	0
Proceeds from share issues	0	0	0	0	0	0
Share repurchases	(14)	(200)	(1,579)	0	0	0
Others	(279)	626	(468)	(1)	(1)	(1)
<b>Net cash from financing</b>	<b>(1,904)</b>	<b>(2,301)</b>	<b>(5,253)</b>	<b>(2,455)</b>	<b>(3,293)</b>	<b>(4,225)</b>
<b>Net change in cash</b>						
Cash at the beginning of the year	9,060	10,298	12,015	6,777	9,671	11,655
Exchange difference	14	5	3	0	0	0
Others	0	0	0	0	0	0
<b>Cash at the end of the year</b>	<b>8,001</b>	<b>12,015</b>	<b>6,777</b>	<b>9,671</b>	<b>11,655</b>	<b>14,403</b>
<b>GROWTH</b>	<b>2022A</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>						
Revenue	11.0%	1.7%	(7.8%)	(7.1%)	6.2%	7.1%
Gross profit	5.3%	(0.4%)	(8.5%)	(12.7%)	10.1%	11.4%
Operating profit	11.5%	(1.8%)	(23.2%)	6.4%	34.4%	27.6%
Net profit	9.6%	(2.6%)	(28.6%)	14.0%	34.2%	28.3%
<b>PROFITABILITY</b>	<b>2022A</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>						
Gross profit margin	71.9%	70.5%	70.0%	65.7%	68.1%	70.9%
Operating margin	24.5%	23.6%	19.7%	22.6%	28.5%	34.0%
Return on equity (ROE)	22.2%	19.2%	13.3%	14.7%	18.2%	21.1%
<b>GEARING/LIQUIDITY/ACTIVITIES</b>	<b>2022A</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>						
Net debt to equity (x)	(0.4)	(0.4)	(0.2)	(0.3)	(0.3)	(0.4)
Current ratio (x)	2.7	2.6	2.3	2.4	2.7	3.1
Receivable turnover days	87.7	120.5	131.4	131.4	131.4	131.4
Inventory turnover days	107.4	123.5	131.2	131.2	131.2	131.2
Payable turnover days	319.6	349.4	367.1	367.1	367.1	367.1
<b>VALUATION</b>	<b>2022A</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>						
P/E	16.7	17.3	23.2	20.1	14.9	11.6
P/E (diluted)	16.7	17.3	23.2	20.1	14.9	11.6
P/B	3.2	2.9	3.0	2.7	2.5	2.2
P/CFPS	13.3	24.3	22.1	13.4	13.5	10.9
Div yield (%)	2.1	2.7	2.6	2.5	3.3	4.3

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

### For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.